ESR2 and neoplasm: Altered response to oestrogen and ER modulators between ER-α and ER-β in relation to receptor DNA binding, activation of target genes and in vivo tumour formation has been described (Paech et al, 1997; Paruthiyil et al, 2004), leading to the possibility that the two ER isoforms may have distinct roles in disease progression.